Benefits
Immune improvement RCT (, LDH cytotoxicity)
A randomized, double-blind, placebo-controlled trial tested PL extract for immunity improvement, using a lactate dehydrogenase (LDH) cytotoxicity assay as the primary endpoint, reflecting Korean regulatory pathway requirements for functional supplements and medicines.
Sanghuang 8-week immune RCT 98-patient
A randomized double-blind placebo-controlled trial gave participants PL mycelium extract (KCTC0399BP strain, 1,000 mg/day) versus placebo for 8 weeks, measuring NK cell activity, TNF-α, IFN-γ, interleukins, and immunoglobulins. Evidence is strain-specific (KCTC0399BP) — generic Phellinus products may not be equivalent.
Pancreatic cancer adjunct (Memorial Sloan Kettering note)
Memorial Sloan Kettering Cancer Center notes one study suggests PL may help as an add-on in some pancreatic cancer patients, with a few case reports of regression in liver and prostate cancers. Honest framing: well-designed trials are needed to confirm — current evidence is preliminary and case-report level.
Antitumor immunomodulatory mechanism
In preclinical work, PL polysaccharides activate macrophages, B cells, and NK cell cytotoxicity, while bioactive small molecules (hispolon, caffeic acid, davallialactone, interfungins A, inoscavin A) contribute additional anti-cancer activity. Mechanistic evidence only.
MeshimaMax combination preclinical
MeshimaMax (PL plus Sasa senanensis bamboo and Chaga) is a preclinical combination active in S180 mouse sarcoma, AOM/DSS colon cancer, and DMBA breast cancer models, with chemotherapy enhancement. This is multi-mushroom combination work, not isolated PL evidence.
Honest framing — pemphigus worsening case report (autoimmune caution)
A documented case report of pemphigus worsening with PL supplementation. Significant autoimmune contraindication — the immune-activation mechanism that drives the immune-support benefit may exacerbate autoimmune conditions. Avoid in pemphigus, lupus, MS, RA, autoimmune thyroid conditions, and similar diagnoses.
Mulberry-tree parasitic origin (TCM heritage)
PL is selectively parasitic on mulberry trees (Morus species) — distinguishing biology from saprophytic medicinal mushrooms. The mulberry-host specificity has TCM significance and may contribute to the bioactive profile via tree-derived precursors. Korean and Japanese traditional medicine emphasize the mulberry-host origin.
Mechanism of action
Polysaccharide immune cell activation
PL polysaccharides activate macrophage cytokine production, B-cell function, and NK cell cytotoxicity via pattern recognition receptor pathways (Dectin-1, TLR2/4) — standard medicinal mushroom β-glucan-type biology with PL-specific structural variants.
Hispolon and bioactive small molecules
Hispolon, caffeic acid, davallialactone, interfungins A, and inoscavin A are PL-specific small molecules with documented antioxidant, anti-inflammatory, and anti-cancer activities in preclinical models.
Cell proliferation and apoptosis modulation
PL extracts modulate cancer biology gene regulation in cellular models — affecting proliferation pathways and apoptosis induction. Preclinical mechanism work supporting the antitumor research program.
Macrophage phagocytosis activation
PL extracts enhance macrophage phagocytic activity in RAW264.7 cells against yeast cells and synthetic nanoparticles — innate immune mechanism supporting the immune-function endpoints.
Cancer cell selectivity (preclinical)
PL extracts show preferential cancer cell sensitivity (IC50 >1 mg/mL with normal cells 2-3× more tolerant) in some preclinical models. Selectivity index supports the integrative-oncology research interest, though human translation is preliminary.
Th1/Th2 immune balance modulation
PMC8627044 measured multi-cytokine endpoints (TNF-α, IFN-γ, IL-1β/2/6/12) reflecting Th1/Th2 balance modulation. The same immune-activation mechanism that drives the benefits is the source of the autoimmune caution.
Clinical trials
CONSORT-randomized double-blinded placebo-controlled trial of PL extract for immunity improvement, with lactate dehydrogenase (LDH) cytotoxicity assay as primary endpoint per Korean regulatory pathway.
Clinical population described in trial publication.
CONSORT-randomized double-blinded placebo-controlled trial of PL extract for immunity improvement, with lactate dehydrogenase (LDH) cytotoxicity assay as primary endpoint per Korean regulatory pathway. First registered clinical trial for PL immune enhancement.
Ku YH, Lee H, Ryu HY, Kang JH 2021 (doi:10.1186/s13063-021-05740-5).
98 participants
Ku YH, Lee H, Ryu HY, Kang JH 2021 (doi:10.1186/s13063-021-05740-5). Randomized double-blind placebo-controlled trial in 98 participants on PL mycelium extract (KCTC0399BP strain, 1,000 mg/day) for 8 weeks. Multi-cytokine endpoints (NK cell activity, TNF-α, IFN-γ, IL-1β/2/6/12, IgG/IgM). Daejeon University College of Korean Medicine and Cheonan Korean Medicine Hospital. Strain-specific (KCTC0399BP).
Comprehensive review of P. linteus antitumor mechanisms.
Clinical population described in trial publication.
Comprehensive review of P. linteus antitumor mechanisms. Polysaccharides activate macrophages, B cells, and NK cell cytotoxicity. Bioactive small molecules (hispolon, caffeic acid, davallialactone, interfungins A, inoscavin A) contribute additional anti-cancer activity. Preclinical mechanism evidence — clinical translation remains limited.